IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. - Hack SP; Spahn J; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Chow P; Qin S (Future oncology (London, England), 2020)